Smoking, typically not associated with health benefits, has long been observed to alleviate symptoms in individuals with colitis while exacerbating conditions in those with Crohn’s disease. The perplexing nature of this phenomenon has intrigued researchers for decades. Both colitis and Crohn’s fall under the category of inflammatory bowel diseases (IBDs), with colitis causing inflammation in the colon lining and Crohn’s manifesting as inflamed patches throughout the digestive tract, affecting various layers of the bowel wall. Recent research from the RIKEN Center for Integrative Medical Sciences in Japan delves into the underlying mechanism behind this smoking paradox, shedding light on the role of bacterial migration in gut health.
In an era where the microbiome is increasingly recognized for its impact on human health, the RIKEN researchers directed their focus towards unraveling the mysteries of the gut ecosystem. Specifically, they sought to investigate whether smoking facilitates the proliferation of certain gut bacteria that could elucidate its divergent effects on different IBDs. Their investigations revealed a notable presence of Streptococcus, a bacteria commonly inhabiting the oral cavity, thriving in the mucous layer of the inner intestinal wall exclusively in smokers. Unlike the usual transient passage of oral bacteria through the digestive system, smoking seemed to provide a conducive environment for these bacteria to establish themselves in the colon.
Further probing into the mechanism, the researchers explored gut metabolites, the products of food breakdown in the intestines. Among smokers, elevated levels of a metabolite called hydroquinone were identified, which in turn supported the colonization and growth of mouth-derived bacteria, including Streptococcus, in the gut. The pivotal question of why the presence of oral bacteria in the gut exhibited contrasting effects on ulcerative colitis and Crohn’s disease patients prompted the researchers to delve deeper into immune responses mediated by Th1 cells.
Through meticulous mouse studies, the researchers uncovered that oral bacteria thriving in the gut triggered the activation of helper Th1 cells, known for their immune-regulatory functions. In individuals with colitis, the Th1 cells effectively suppressed the inflammatory response, thereby alleviating symptoms. Conversely, in Crohn’s disease, where inflammation is driven by Th1 cells themselves, an abundance of activated Th1 cells in the gut exacerbated the condition. While the researchers do not endorse smoking as a therapeutic approach for ulcerative colitis due to its well-established detrimental effects, they believe that their findings offer valuable insights into the pathophysiology of IBDs and potential avenues for targeted treatments.
Lead researcher Hiroshi Ohno emphasizes the significance of their findings in elucidating the mechanism through which smoking exerts protective effects against ulcerative colitis, attributing it to the relocation of oral bacteria to the gut, particularly Streptococcus species, and the ensuing immune response in the intestinal milieu. He suggests that targeting this specific bacterial population or utilizing compounds like hydroquinone could potentially emulate the beneficial effects of smoking without the associated health risks. This groundbreaking research, elucidating the intricate interplay between smoking, gut microbiota, and immune responses in IBDs, has been published in the esteemed journal, Gut.
Takeaways:
– Smoking paradox in inflammatory bowel diseases involves the relocation of oral bacteria to the gut, influencing immune responses differently in colitis and Crohn’s disease.
– Streptococcus bacteria from the oral cavity thrive in the gut of smokers, modulated by elevated levels of hydroquinone.
– Th1 cells play a crucial role in mediating the contrasting effects of oral bacteria on inflammation in colitis and Crohn’s disease.
– Insights from this research offer potential avenues for developing targeted therapies for ulcerative colitis based on the microbiome-immune axis.
Tags: microbiome
Read more on newatlas.com